Clinical trial
Study Evaluating Bifeprunox in Bipolar Depression
NCT00245973 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00245973 |
|---|---|
| Title | Study Evaluating Bifeprunox in Bipolar Depression |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Bifeprunox in the Treatment of Depression in Outpatients With Bipolar Disorder |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Collaborators | Solvay Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Depression Bipolar |
| Intervention type | Drug |
| Interventions | Bifeprunox |
| Enrollment | 380 |
| Start date | Jun 1, 2005 |
| Completion | Oct 1, 2007 |
| First posted | Oct 28, 2005 |
| Last update posted | Dec 5, 2007 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: